Segall Bryant & Hamill’s Amneal Pharmaceuticals AMRX Stock Holding History

Segall Bryant & Hamill’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Sell	240,060 -37,742	-14%	-$517K	0.05%	341
2026 Q1	$3.45M	Sell	277,802 -113,969	-29%	-$1.53M	0.05%	349
2025 Q4	$4.94M	Sell	391,771 -3,992	-1%	-$45.7K	0.07%	318
2025 Q3	$3.96M	Sell	395,763 -24,530	-6%	-$220K	0.05%	336
2025 Q2	$3.4M	Sell	420,293 -39,151	-9%	-$295K	0.05%	359
2025 Q1	$3.85M	Sell	459,444 -10,917	-2%	-$91.1K	0.06%	347
2024 Q4	$3.73M	Sell	470,361 -18,801	-4%	-$158K	0.05%	374
2024 Q3	$4.07M	Buy	489,162 +7,661	+2%	+$59.9K	0.06%	358
2024 Q2	$3.06M	Buy	+481,501	New	+$3.06M	0.05%	343

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Segall Bryant & Hamill's AMRX Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its Amneal Pharmaceuticals (AMRX) stake by 14% in Q2 2026, selling an estimated $517K and leaving 240,060 shares worth $4.16M. The position accounts for 0.05% of the portfolio, ranked #341.

Segall Bryant & Hamill first reported a position in AMRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.94M in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Segall Bryant & Hamill held 240,060 shares of Amneal Pharmaceuticals worth $4.16M as of Q2 2026.
Segall Bryant & Hamill sold 37,742 Amneal Pharmaceuticals shares in Q2 2026, an estimated $517K.
Amneal Pharmaceuticals made up 0.05% of Segall Bryant & Hamill's portfolio in Q2 2026, its #341 holding.
Segall Bryant & Hamill first reported a position in Amneal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Segall Bryant & Hamill's Amneal Pharmaceuticals position peaked at $4.94M in Q4 2025.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.